ResearchAndMarkets.com's offering.
The report provides an in-depth analysis of the KRAS inhibitorsKRAS inhibitors market, epidemiology, and market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. KRAS mutations contribute less to cancer in Japan compared to Western countries like the United States and Europe. The United States is expected to hold the highest market share for KRAS inhibitorsKRAS inhibitors in 2022, followed by the EU4 countries, with Germany having the highest share and Spain the lowest. KRAZATI has been added as a therapeutic option after first-line treatment for NSCLC in the latest NCCN guidelines published in December 2022. There is an opportunity for emerging KRAS key players focusing on safer combinations with less toxicity. LUMAKRAS witnessed a decrease in sales after the launch of KRAZATI, primarily due to a price adjustment implemented as part of a reimbursement agreement in Germany. Several companies are developing candidates for pan-KRAS inhibition, which has the potential to create a positive shift in the KRAS-inhibitorsKRAS-inhibitors market. The report covers the epidemiology of KRAS inhibitorsKRAS inhibitors in NSCLC, CRC, and pancreatic cancer, as well as the total KRAS-mutated cases in the 7MM (United States, EU4, UK, and Japan). The total KRAS-mutated cases in the 7MM were over 450,000 in 2022 and are projected to increase during the forecast period. The United States is expected to have the highest market share among the 7MM in 2022 for KRAS inhibitorsKRAS inhibitors. LUMAKRAS is anticipated to capture more market share compared to KRAZATI throughout the study period. The report also includes insights from key opinion leaders (KOLs) and industry experts working in the domain to understand current treatment patterns and market trends.
Overall, the KRAS inhibitorsKRAS inhibitors market is evolving rapidly with recent approvals and ongoing research for new therapies targeting different KRAS mutations and multiple cancer types. The market holds significant potential for growth as more effective and safer treatments are developed to address various KRAS variants. 5. Epidemiology and Market Forecast Methodology
6. Disease Background and Overview
9. Epidemiology and Patient Population
15. Market Access and Reimbursement
A selection of companies mentioned in this report includes:
For more information about this report visit https://www.researchandmarkets.com/r/7yd9kv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets